Medmix Ag · SIX:MEDX
Medmix — March 2023 equities conferences
18 slides from Medmix's conference presentation, March 2023
Slide 1: medmix
medmix CONFIDENTIAL
Slide 2: Investor Presentation March 2023
Investor Presentation March 2023 medmix CONFIDENTIAL
Slide 3: The safe harbor statement under the US private securities litigation reform act 1995
The safe harbor statement under the US private securities litigation reform act 1995 This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and
Slide 4: Business Review
Business Review medmix CONFIDENTIAL
Slide 5: 2022 highlights
2022 highlights • Strong performance with backdrop of volatile geopolitical and market conditions - Record revenue of CHF 477 million, +5.7%1 YoY - 22% Adjusted EBITDA margin - CHF 10 million free cash flow • Launch of innovative PiccoJect™, Micro Bristle Applicator and greenLine™ cartridge • New US
Slide 6: medmix in 2022
medmix in 2022 Global footprint 14 ~2,100 production, logistics and distribution employees sites 22% ~2.4bn CHF 477m revenue adj. EBITDA margin Products per year ~900 active patents 6 medmix CONFIDENTIAL
Slide 7: 2022 Revenue by Segments
2022 Revenue by Segments Healthcare Consumer and Industrial ("C&I") Drug Dental Surgery Industry Beauty Delivery 125.1 + 5.8% 47.0 + 21.4% 12.8 + 1.3% 148.2 - 8.2% 144.1 + 18.6% Strong performance Higher demand from Growth in tissue bank Continued demand from Volume driven increase with especially i
Slide 8: Sustainability at medmix in 2022
Sustainability at medmix in 2022 medmix Group • Completed the first CDP Climate Change assessment, achieving an “Awareness” rating - equaling the industry average - 3 years ahead of target • Committed to the UN Global Compact, supporting and acting to achieve the Sustainable Development Goals • Comm
Slide 9: Financial review
Financial review medmix CONFIDENTIAL
Slide 10: 2022 Results
2022 Results Growth and resilience CHF millions Key figures Highlights • Revenue growth above top end of adjusted guidance 2022 2021 YOY adj.1 Correcting for Poland YoY growth +11.8% Revenue 477.1 457.3 4.3% 5.7% • BA Gross Profit Margin % -250 bps YoY driven by - time lag in price increases v cost
Slide 11: Healthcare
Healthcare Growth across all Healthcare Segments Key figures Revenue split Surgery In CHF millions 2022 2021 YoY1 7% Revenue 184.9 169.8 9.2% (2021: 8%) Business Area Gross Profit 112.7 103.2 9.5m Business Area Gross Profit margin % 61.0% 60.8% +0.2pts Drug Delivery 25% Dental Highlights (2021: 24%)
Slide 12: Consumer & Industrial
Consumer & Industrial Growth in Beauty and resilience in Industry Key figures Revenue split In CHF millions 2022 2021 YoY1 Revenue 292.3 287.5 +3.6% Business Area Gross Profit 105.3 117.1 -11.8m Business Area Gross Profit margin % 36.0% 40.7% -4.7pts Industry Highlights 51% Beauty 2022 (2021: 56%) 4
Slide 13: Outlook
Outlook medmix CONFIDENTIAL
Slide 14: Outlook
Outlook FY2023 • Revenue: 5 – 7% organic growth as demand continues to normalize • Adjusted EBITDA margin: 100bps YoY to 23% through • return to full capacity and an improving cost base in C&I • an improved revenue mix overall • Capex: 9% revenue excluding Valencia spend (14% revenue total) Mid-term
Slide 15: Outlook – segment market trends
Outlook – segment market trends Underpinned by attractive fundamental macro trends Market growth forecast post Macro trends recovery to 2025E (CAGR)1,2 Main segment trends • Aging population Growing Dental middle-class market 2% • Emerging markets shift away from hand- to device-mixing • Trend to un
Slide 16: Outlook - Segments
Outlook - Segments Healthcare Consumer and Industrial ("C&I") Drug Dental Surgery Industry Beauty Delivery Normalized demand Outlook supported by Expected growth ahead Outlook supported by key Market forecast supports expected in FY2023 – current project pipeline of market forecast from industries e
Slide 17: Outlook - Drug Delivery
Outlook - Drug Delivery Expected revenue development Current projects delivering product revenues in 2026 by clinical stage +29% Phase 2 Phase 3 Market Authorization Expected 2026 product revenues by indication (based on current serial products and current projects) Growth disorders and related Fert
Slide 18: Your Investor Relations contact
Your Investor Relations contact Sheel Gill Head of M&A, Strategy and Investor Relations, medmix Phone: +41 41 723 73 57 Mobile: +41 79 346 41 72 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland medmix CONFIDENTIAL